RELAPSED OR REFRACTORY B CELL NON HODGKIN LYMPHOMA
Clinical trials for RELAPSED OR REFRACTORY B CELL NON HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED OR REFRACTORY B CELL NON HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED OR REFRACTORY B CELL NON HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Dual-Targeting CAR-T therapy shows promise for tough lymphoma
Disease control OngoingThis study tests a new treatment called prizloncabtagene autoleucel (prizlo-cel) for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to other treatments. The therapy uses a patient's own immune cells, which are modified in a lab to better recognize and…
Matched conditions: RELAPSED OR REFRACTORY B CELL NON HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New CAR-T therapy targets tough lymphoma in early trial
Disease control OngoingThis early-phase trial is testing a new treatment called JNJ-90009530, a type of CAR-T cell therapy that targets a protein called CD20 on lymphoma cells. The study includes 21 adults with relapsed or refractory B-cell non-Hodgkin lymphoma who have already tried other treatments. …
Matched conditions: RELAPSED OR REFRACTORY B CELL NON HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New hope for tough lymphomas? daily pill trial launches
Disease control OngoingThis phase II trial tests the drug pemigatinib (Pemazyre) in 27 adults with relapsed or refractory B-cell non-Hodgkin lymphomas, including mantle cell and marginal zone lymphoma. Participants take one pill daily in 28-day cycles. The main goal is to see if the drug can shrink tum…
Matched conditions: RELAPSED OR REFRACTORY B CELL NON HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: University of Utah • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New cocktail of three drugs targets Hard-to-Treat lymphoma
Disease control OngoingThis early-phase trial is testing whether combining three drugs—tazemetostat, zanubrutinib, and an anti-CD20 antibody (rituximab or obinutuzumab)—is safe and effective for people with certain types of lymphoma that have come back or not responded to treatment. The study involves …
Matched conditions: RELAPSED OR REFRACTORY B CELL NON HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: University of Utah • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Radiation boost may help CAR t therapy work better for tough lymphomas
Disease control OngoingThis early-phase study tests whether giving radiation therapy before standard CAR T cell treatment is safe and practical for people with B-cell lymphoma that has come back or not responded to prior treatments. About 20 participants will receive split-course bridging radiation to …
Matched conditions: RELAPSED OR REFRACTORY B CELL NON HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC